The Pentagon is temporarily rescinding recently published clinical guidance for a new, mandatory testosterone deficiency screening policy for service members aged 30 and older, according to a U.S. official who spoke on Thursday.
On Wednesday, the Pentagon posted the document titled “Clinical Guidance for Health and Human Performance Optimization” on its website. By Thursday, however, the memo and an accompanying statement from spokesperson Sean Parnell had been removed from public view, leaving “Page Not Found” banners on both the Pentagon and Defense Health Agency websites.
The draft document published on September 2, 2026, was temporarily rescinded to allow for updates, the official said, noting that interim guidance remains in effect. The detailed clinical guidelines had laid out separate testosterone deficiency screening paths for men and women that were scheduled to take place during their annual health assessments.
Policy Scope and Screening Procedures
The guidance was set to take effect immediately. According to the Pentagon, the initiative aimed to improve military readiness by identifying and managing hormonal and energy-availability issues among troops.
Under Wednesday’s guidance, men aged 30 and older would have been screened through a questionnaire that could then trigger a blood test for testosterone levels and, if needed, testosterone hormone therapy. Women would also have been screened through a questionnaire, which could then move to treatment for conditions related to hormonal imbalance. The policy specified that testosterone would be used in women only for diagnoses with evidence of efficacy, such as Hypoactive Sexual Desire Disorder, which is characterized by a distressing level of low sexual interest.
Did You Know? The “Clinical Guidance for Health and Human Performance Optimization” was posted on the Pentagon website on September 2, 2026, before being removed by the following day.
Expert Reactions and Context
U.S. Defense Secretary Pete Hegseth, who has promoted the use of testosterone, announced the screening mandate in July. That announcement raised questions among experts about whether there was a scientific basis for such a policy. The U.S. Food and Drug Administration plans to hold a meeting in mid-September of experts to discuss the medical use of testosterone.
Doctors have raised concerns that broad testosterone testing could lead to unnecessary or potentially harmful treatment. According to medical professionals, there is little evidence that universal screening for low testosterone among military personnel would improve U.S. combat readiness.
Frequently Asked Questions
Who is affected by the testosterone screening policy?
The policy applies to service members aged 30 and older, with separate screening paths outlined for men and women during their annual health assessments.
What happened to the published guidelines?
The Pentagon posted the “Clinical Guidance for Health and Human Performance Optimization” on Wednesday but removed the memo and an accompanying statement from spokesperson Sean Parnell by Thursday, replacing the links with “Page Not Found” banners.
Why was the document pulled?
A U.S. official stated that the draft document published on September 2, 2026, was temporarily rescinded to allow for updates, while noting that interim guidance remains in effect.
How will future updates to the military’s health and performance guidelines affect service members undergoing annual assessments?
Worth a look